Novavax, Inc. (NASDAQ:NVAX) reported that it can post vital clinical results from its older adult study in the coming 90 days. It has been in discussion with the U.S. FDA about planning an informational analysis of the Prepare study that would offer an indication of its drug’s potential efficacy.
The company considers that it can conduct this assessment in late 2017. Moreover, management also predicts continued adoption and utilization of its proprietary adjuvant, Matrix-M, in numerous internal and associated programs.
Novavax’s offerings are likely to improve revenue growth prospects given its product advancement capabilities and marketing network in distinct geographies. Notwithstanding company’s positive growth plan, meaningful and substantial contribution from the same is partially inhibited due to large investment needs and still emerging commercialization pathway for its pipeline. Also, the firm is likely to face preliminary integration and gestational concerns.
From technical perspective, Novavax stock remains in a comfortable spot considering its promising pipeline potential. Imminent clinical study and submission of study documents are the imminent key triggers.
Earlier in January, Cantor Fitzgerald assigned ‘Neutral’ rating to NVAX with a price target of $2, while FBR & Co. has a rating of ‘Outperform’ with a price target of $12. Chardan Capital has assigned a rating of ‘Hold’ with a price target of $1.50 on NVAX.
As many as 7 street analysts have rated NVAX with a hold rating, one has assigned a strong buy rating and three have placed a buy rating to the stock. The equity has a consensus recommendation of “Hold”.
Novavax continues enrollment in the RSV Phase III Prepare clinical study for infants through maternal immunization. Enrollment in Q1 2017 expanded to Chile, New Zealand, South Africa, Argentina and Australia. The second season of registration has considerably gained from the establishment of the operational infrastructure and extensive experience from the first international season.